Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M244,204Revenue $M53,634Net Margin (%)39.1Altman Z-Score4.3
Enterprise Value $M249,396EPS $4.1Operating Margin %20.9Piotroski F-Score6
P/E(ttm)25.6Beneish M-Score-2.8Pre-tax Margin (%)22.9Higher ROA y-yY
Price/Book3.210-y EBITDA Growth Rate %1.3Quick Ratio1.2Cash flow > EarningsY
Price/Sales4.65-y EBITDA Growth Rate %-0.6Current Ratio1.4Lower Leverage y-yN
Price/Free Cash Flow24.2y-y EBITDA Growth Rate %14.2ROA % (ttm)16.4Higher Current Ratio y-yY
Dividend Yield %2.6PEG--ROE % (ttm)29.1Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M2,399ROIC % (ttm)11.6Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSDodge & Cox 2015-03-31 Reduce-0.02%$91.67 - $103
($98.99)
$ 101.813%Reduce 0.58%50,032,795
NVSTweedy Browne 2015-03-31 Reduce-0.01%$91.67 - $103
($98.99)
$ 101.813%Reduce 2.19%260,217
NVSHOTCHKIS & WILEY 2015-03-31 Sold Out -0.0031%$91.67 - $103
($98.99)
$ 101.813%Sold Out0
NVSMario Gabelli 2015-03-31 Add$91.67 - $103
($98.99)
$ 101.813%Add 2.61%9,840
NVSKen Fisher 2015-03-31 Reduce$91.67 - $103
($98.99)
$ 101.813%Reduce 0.29%5,990,224
NVSRuane Cunniff 2014-12-31 Sold Out $85.02 - $96.65
($92.56)
$ 101.8110%Sold Out0
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 101.8113%Reduce 98.51%9,646
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 101.8113%New holding7,772
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 101.8116%Reduce 71.80%649,519
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 101.8116%Add 10.04%51,102,219
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 101.8138%Sold Out0
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 101.8140%Sold Out0
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 101.8150%Reduce 85.39%726,200
NVSKahn Brothers 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 101.8150%Reduce 21.03%33,456
NVSVanguard Health Care Fund 2012-12-31 Reduce-0.99%$58.97 - $63.96
($61.82)
$ 101.8165%Reduce 70.59%1,461,400
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 101.8165%Add 2.65%48,438,459
NVSKahn Brothers 2012-12-31 Add0.04%$58.97 - $63.96
($61.82)
$ 101.8165%Add 10.43%42,368
NVSHOTCHKIS & WILEY 2012-12-31 Reduce-0.02%$58.97 - $63.96
($61.82)
$ 101.8165%Reduce 1.98%2,313,613
NVSKen Fisher 2012-12-31 Reduce-0.01%$58.97 - $63.96
($61.82)
$ 101.8165%Reduce 0.93%5,038,879
NVSChris Davis 2012-12-31 Reduce$58.97 - $63.96
($61.82)
$ 101.8165%Reduce 0.09%33,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15578.73view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
      8 Top Healthcare Stocks to Watch May 13 2015 
      Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
      Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
      Amgen’s Q1 Earnings Paints An Overall Positive Image To Investors Apr 22 2015 
      In Europe Really Recovering? Apr 19 2015 
      Amgen’s First Drug For Cardiovascular Disease Gets The Green Light Apr 17 2015 
      Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 
      Biotech Momentum Indicators: Achaogen (AKAO), Novartis (NVS), VIVUS (VVUS) Apr 01 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 

      More From Other Websites
      Early movers: TIF, KORS, TOL, BWS, HRL & more May 27 2015
      Novartis digs into health tech with bet on "robotic pill" May 27 2015
      Novartis digs into health tech with bet on 'robotic pill' May 27 2015
      Novartis digs into health tech with bet on "robotic pill" May 27 2015
      Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA » May 27 2015
      5:02 pm Novartis AG has entered into a collaboration with Rani Therapeutics to evaluate Rani's novel... May 26 2015
      Pharma Trumps All Healthcare Sectors In Executive Compensation May 26 2015
      Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog May 22 2015
      Novartis' Summer Blockbuster LCZ696 Gains A Name, Skips An Advisory Panel May 22 2015
      Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced... May 21 2015
      Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 » May 20 2015
      Buckingham's Top Four New Buys of First Quarter Go Up in Price May 15 2015
      Why Clovis is Getting Clobbered May 15 2015
      Is Sir Andrew Witty The Person To Lead A Major Pharmaceutical Company? May 14 2015
      Possible Investment Contest May 13 2015
      GSK's Curious Oncology Research Position -- A Recipe For Failure? May 12 2015
      Novartis' Zykadia Approved in the EU for Lung Cancer - Analyst Blog May 11 2015
      GlaxoSmithKline: Out of step May 11 2015
      ​Amgen wins injunction against Novartis' biosimilar drug May 08 2015
      Pharmalot.. Pharmalittle.. As the Weekend Nears: We're Catching up on Amgen, Sanofi and Much More!! May 08 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK